What is PMOS and why did PCOS just get renamed?

PCOS, polycystic ovary syndrome, was officially renamed PMOS, polyendocrine metabolic ovarian syndrome, on May 12, 2026, following the publication of a landmark global consensus paper in The Lancet. The name change reflects more than a decade of scientific work and input from over 22,000 people across six continents. The core reason: the old name was factually inaccurate, focused attention on the wrong part of the body, and contributed to decades of missed diagnoses, fragmented care, and unnecessary stigma for millions of women. PMOS is the name the science has been pointing toward for years.

What PCOS was, and why the name was always a problem

Polycystic ovary syndrome took its name from a feature that turned out to be neither defining nor always present: the appearance of multiple follicles on the ovaries during ultrasound. These were described as cysts, and the name stuck, even as researchers spent decades documenting that the condition was far more complex than a problem with the ovaries.

As the Lancet consensus paper states, the term PCOS was inaccurate because it implied pathological ovarian cysts that are not actually present in the condition. What appears on ultrasound are arrested follicles, not true cysts. Naming the condition after structures that were neither pathological nor definitional sent both patients and providers looking in the wrong place.

The result, documented across decades of research: up to 70 percent of women with the condition remained undiagnosed, according to the World Health Organization. Women who did not present with visible ovarian changes on ultrasound were dismissed or delayed. And the metabolic, endocrine, and psychological dimensions of the condition received far less clinical attention than the reproductive ones.

"I was told early in my life that I may never be able to have children. I have six. I believe deeply that healing starts from within, with foundational nutrition, with how you support your body, and yes, with the language you use around your body. This name change matters because language shapes how women understand themselves and how doctors treat them."

— Amy Suzanne Upchurch, Founder and CEO of Pink Stork

What PMOS means, word by word

The new name was not chosen casually. It was selected after global surveys, international workshops, and a rigorous consensus process led by Professor Helena Teede of Monash University in Australia, alongside 56 leading academic, clinical, and patient organizations.

Polyendocrine means that multiple endocrine glands and hormonal systems are involved. The condition is not an isolated ovarian disorder. It involves disturbances across the insulin signaling system, androgen production, and neuroendocrine pathways. As the Endocrine Society explains, this name better describes PMOS as an endocrine or hormone condition with widespread impacts throughout the body.

Metabolic acknowledges that insulin resistance and metabolic dysfunction are central to the condition for most women who have it, not peripheral complications. This single word shifts the entire clinical frame from reproductive management to metabolic care.

Ovarian is retained because the ovaries are genuinely involved in the condition's effects, including effects on ovulation, follicular development, and androgen production. The ovaries are downstream of the metabolic and endocrine drivers, but they are still part of the picture.

Syndrome acknowledges that this is a collection of features that appear together but do not have a single cause or a single presentation. PMOS shows up differently in different women, and the treatment approach must be individualized accordingly.

How this name change came to happen

The journey to PMOS began formally in 2015, at a meeting in Sicily where experts attempted to address the naming problem and, by most accounts, could not agree. The disagreement itself reflected how deeply the old name had shaped clinical thinking. Over the following decade, a more structured process took shape.

Professor Teede led a three-phase international effort that included global surveys, modified Delphi methods, nominal group workshops, and marketing assessments. The process drew responses from more than 22,000 stakeholders across all world regions, according to STAT News. Participants were asked what they wanted a new name to accomplish. The primary answer was avoiding stigma, followed by ease of communication and scientific accuracy.

Three candidate names were tested in final workshops. PMOS won in a landslide. The consensus was announced at the European Congress of Endocrinology in Prague and published simultaneously in The Lancet.

"The midlife transition has really been forgotten historically in women's healthcare."

— Jessica Nazzaro, DO, FACOG, NCMP, Board-Certified OB-GYN and National Certified Menopause Practitioner

What the name change does and does not change right now

The name change does not immediately alter diagnostic criteria. Doctors will still use the same core criteria they have been using: irregular or absent ovulation, signs of excess androgens such as acne, excess body or facial hair, or hair thinning, and ultrasound findings. These criteria remain valid under the new name.

What the name change is designed to shift is clinical framing, research funding, insurance classification, public understanding, and the conversations women have with their providers. A three-year transition period is underway, with updates planned to clinical guidelines, medical education curricula, and international disease classification systems in 195 countries, according to Contemporary OB/GYN.

During the transition, both terms will appear in medical literature and clinical settings. If your provider still uses the term PCOS, that is expected. The change will phase in over time as guidelines and coding systems are updated.

Why this matters for women who have been living with this condition

For women who have had this condition for years, sometimes decades, the name change can feel like a validation that was a long time coming. Many women describe years of being dismissed, misdiagnosed, or told their symptoms were unrelated to a condition that was actually affecting multiple systems of their body simultaneously.

The new name signals, formally and scientifically, that this is a complex, multisystem condition that deserves comprehensive care. It is not a fertility problem with some skin side effects. It is a whole-body endocrine and metabolic condition that happens to affect reproduction among many other things.

Lorna Berry, an Australian woman with PMOS who played a key role in the renaming process, described the outcome as being "about accountability and progress," and about her daughters, their daughters, and the countless women yet to be born, as reported by the Endocrine Society.

For more on what this shift means for diagnosis and treatment, see our guide on how the PCOS to PMOS name change will affect diagnosis and treatment. For the science behind the metabolic dimension of the condition, see what PMOS and insulin resistance have to do with each other.

Frequently asked questions

Is PCOS officially renamed PMOS?

Yes. The name change was published in The Lancet on May 12, 2026, following a 14-year global consensus process involving 56 academic, clinical, and patient organizations and input from more than 22,000 people worldwide. The new official name is polyendocrine metabolic ovarian syndrome, or PMOS.

What does PMOS stand for?

PMOS stands for polyendocrine metabolic ovarian syndrome. Polyendocrine refers to the involvement of multiple hormonal systems. Metabolic acknowledges the central role of insulin resistance and metabolic dysfunction. Ovarian recognizes that the ovaries are involved in the condition's effects. Syndrome indicates a collection of features without a single cause.

Why was PCOS a misleading name?

The term PCOS implied the presence of pathological ovarian cysts, which are not actually a feature of the condition. The structures seen on ultrasound are arrested follicles, not true cysts. The name focused clinical attention on the ovaries and reproductive function while obscuring the metabolic, endocrine, and psychological dimensions of the condition, contributing to delayed diagnosis and fragmented care.

Does the name change affect my diagnosis or treatment?

The name change does not immediately alter diagnostic criteria or treatment protocols. The same core criteria remain in use. The shift is designed to change clinical framing, research priorities, and how the condition is discussed and classified over the next three to five years as guidelines and coding systems are updated worldwide.

Will doctors still use the term PCOS?

During the three-year transition period, both terms will appear in clinical and research settings. Your provider may continue using PCOS while guidelines and classification systems are updated. This is expected and does not mean the name change is not happening. The transition is designed to be gradual and deliberate.

How many women are affected by PMOS?

According to the Endocrine Society and The Lancet consensus paper, PMOS affects more than 170 million women worldwide, approximately 1 in 8 women. The World Health Organization estimates that up to 70 percent of those affected remain undiagnosed.

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any new supplement, especially during pregnancy, breastfeeding, or while managing a medical condition. Keep out of reach of children.